Observational Study of Sex Differences in Symptoms During... | NCT06562777

ID	Type	Description	Link
NCI-2023-06611	Registry Identifier	CTRP (Clinical Trial Reporting Program)
STUDY00025328	Other Identifier	OHSU Knight Cancer Institute

Status Module

Name	Class
Oregon Health and Science University	OTHER

Description Module

Label	Type	Description	Intervention Names
Observational		Patients complete surveys and have their medical records reviewed on study.	Other: Non-Interventional Study

Name	Type	Description	Arm Group Labels	Other Names
Non-Interventional Study	Other	Non-Interventional Study	Observational

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Patient-reported symptoms	Will compare the number, severity, and burden of symptoms by sex. Will be assessed using the Common Toxicity Criteria and Adverse Events v1.0 (PRO-CTCAE) reporting tool.	Baseline, weekly thereafter up to 26 weeks
Patient-reported QOL - Part 1	Will use the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29)	Baseline, month 3, month 6
Patient-reported QOL - Part 2	PROMIS Cognitive Function instruments	Baseline, month 3, month 6
Patient-reported QOL - Part 3	Selected questions from the EORTC-QLQ-C30 to evaluate the impact of immunotherapy on QOL.	Baseline, month 3, month 6
Clinician-assessed patient symptoms	Clinicians will rate patient symptoms according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scoring system, which grades adverse events according to 5 categories of severity and requires evaluation of the extent to which the adverse event can be attributed to treatment ("unrelated" to "definite"). Will examine agreement using intraclass correlations by patient gender.	Baseline, month 3, month 6

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Age 18 years or older on date of enrollment (Confirmed by review of the date of birth as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
Histologically confirmed diagnosis of cancer and plan to begin SOC immunotherapy for the treatment of cancer per FDA approval and/or National Comprehensive Cancer Network (NCCN) guidelines (Confirmed by review of cancer diagnosis and treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
Treating oncologist anticipates at least 6 consecutive months of SOC immunotherapy (Confirmed by review of the treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)

Exclusion Criteria:

Diagnosed with breast, prostate, testicular, penile, or gynecologic cancer (Confirmed by review of the cancer diagnosis as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
Previously received immunotherapy (Confirmed by review of cancer treatment history as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
Life expectancy of <6 months at time of enrollment per the treating oncologist (Confirmed by the professional opinion of the treating oncologist and subsequently recorded in a CRF.)
Concurrently receiving a non-immunotherapy treatment, including chemotherapy, biological, or targeted therapy (Confirmed by review of the treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
Concurrently receiving radiation, unless hypofractionated palliative radiation prescribed to alleviate poorly controlled symptoms (e.g. pain) (Confirmed by review of the treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
Participation in a clinical trial of experimental immunotherapy (Confirmed by review of the treatment plan as documented in the Electronic Medical Record (EMR) and subsequently recorded in a CRF.)
Needs to rely on a proxy to complete patient-reported outcome instruments (Confirmed by self-report on Health History Questionnaire.)
Unwilling or unable to complete consent form and surveys electronically (Confirmed by successful completion of electronic consent form and baseline survey in REDCap.)

Assessment of participant eligibility is at the discretion of the Principal Investigator, Dr. Deanne Tibbitts.